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Abstract  
AKT is an enzyme of the PI3K/pAKT pathway, regulating proliferation and cell survival. High 
basal levels of active, phosphorylated AKT (pAKT) are associated with tumor progression 
and therapeutic resistance in some breast cancer subtypes, including HER2 positive breast 
cancers. Various stimuli can increase pAKT levels and elevated basal pAKT levels are a 
feature of PTEN-deficient breast cancer cell lines. The aim of this study was to develop an 
assay able to identify modulators of pAKT levels using an automated epifluorescence 
microscope and high content analysis. To develop this assay, we used HCC-1569, a PTEN-
deficient, HER2-overexpressing breast cancer cell line with elevated basal pAKT levels. 
HCC-1569 cells were treated with a selective pharmacological inhibitor of AKT (MK-2206) to 
reduce basal pAKT levels or EGF to increase pAKT levels. Immunofluorescence images 
were acquired using an automated epifluorescence microscope and integrated intensity of 
cytoplasmic pAKT staining was calculated using high content analysis software. Mean and 
median integrated cytoplasmic intensity were normalized using fold change and standard 
score to assess assay quality and to identify most robust data analysis. The highest z’ factor 
was achieved for median data normalization using the standard score method (z' = 0.45). 
Using our developed assay we identified the calcium homeostasis regulating proteins 
TPRV6, STIM1 and TRPC1 as modulators of pAKT levels in HCC-1569 cells. Calcium 
signaling controls a diverse array of cellular processes and some calcium homeostasis 
regulating proteins are involved in modulating pAKT levels in cancer cells. Thus, these 
identified hits present promising targets for further assessment.  
 
Keywords: assay development, automated microscopy, breast cancer, calcium channels, 
gene silencing, high content analysis 
 
Abbreviations 
EGF    Epidermal growth factor  
EGFR    Epidermal growth factor receptor  
EMT    Epithelial mesenchymal transition 
HER2    Human epidermal growth factor receptor 2 
pAKT    Phosphorylated AKT  
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PBS    Phosphate buffered saline 
PBSCM PBS containing calcium and magnesium  
PI3K Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PFA Paraformaldehyde 
PMCA Plasma membrane Ca2+- ATPase 
PTEN    Phosphatase and tensin homolog 
siNT Non-targeting small interfering RNA 
SPCA Secretory pathway Ca2+-ATPase 
STIM Stromal interaction molecule  
TGF-β Transforming growth factor β 
TRPC Transient receptor potential canonical 
TRPV    Transient receptor potential vanilloid 
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Introduction 
Therapeutic responses and disease progression of breast cancers are highly dependent on 
the molecular/clinical subtype and the presence of druggable targets for hormonal or 
molecularly targeted therapy (Blows, et al., 2010). Progress in drug development, targeted 
therapies and early disease detection have improved overall survival for many breast cancer 
patients (Siegel, et al., 2012). However, intrinsic and acquired resistance to molecular 
targeted therapies are a major concern (Gonzalez-Angulo, Morales-Vasquez, & Hortobagyi, 
2007). Hence, there is an urgent need to identify new therapeutic targets that are involved in 
modulating the activity of key enzymes in tumor-associated signaling pathways and 
therapeutic resistance (Luo, Manning, & Cantley, 2003).  
 
A key pathway in regulating cell survival and proliferation is the PIP3/AKT pathway. 
Increased signaling through this pathway is found in many types of cancer and has been 
linked to drug resistance and thus targeting key enzymes of this pathway is of major interest. 
A main regulator of this pathway is AKT, a protein kinase, activated through phosphorylation 
of two residues (serine 473 and threonine 308), which can be initiated via diverse upstream 
mechanisms, e.g. epidermal growth factor (EGF) activation of the EGF receptor (EGFR) 
(Henson & Gibson, 2006; Luo, et al., 2003). AKT activity is enhanced in cancers with loss of 
function mutations or decreased expression of phosphatase and tensin homolog (PTEN), a 
negative AKT modulator (Nagata, et al., 2004). Some breast cancer cell lines, including 
HCC-1569, a human epidermal growth factor receptor 2 (HER2) overexpressing cell line of 
the basal molecular subtype, have a loss of PTEN and hence exhibit elevated levels of basal 
pAKT (Azimi, et al., 2017; deGraffenried, et al., 2004). Upregulated pAKT levels are linked to 
increased cell proliferation, reduced apoptosis and are involved in mediating resistance to 
HER2 targeted therapy and chemotherapy (Clark, West, Streicher, & Dennis, 2002; O'Brien, 
et al., 2010; Yang, et al., 2015). Targeting the PIP3/AKT pathway with pharmacological 
inhibitors represents a strategy to improve current treatment options and could potentially 
overcome resistance mechanisms in some breast cancer patients (ClinicalTrials.gov; Luo, et 
al., 2003; Yap, et al., 2011). 
 
Traditionally immunoblotting or standard immunofluorescence imaging are used to assess 
pAKT levels. However, these methods only allow for low sample throughput and are not 
compatible with automation. One method to increase sample throughput is automated 
epifluorescence microscopy and high content analysis, which has been relatively unexplored 
to identify pAKT modulators in the published literature. High content analysis is a method 
using automated microscopy combined with multi-parameter imaging processing to produce 
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numerical data sets of detected imaging parameters for quantitative image analysis 
(Buchser, et al., 2004). Such an approach allows the fast assessment of pAKT levels in 
individual cells within a large cell population in each well at the same time. 
 
Our study sought to develop such an assay to identify calcium homeostasis regulating 
proteins that modulate basal pAKT levels. Calcium signaling plays an important role in a 
diverse array of cellular processes relevant to tumor progression including proliferation, 
migration and apoptosis (Monteith, Davis, & Roberts-Thomson, 2012). Many breast cancers 
show altered expression of specific calcium channels and/or calcium pumps (Monteith, et al., 
2012). Pharmacological inhibition or silencing of some of these calcium channels or pumps 
reduces breast cancer cell proliferation and/or invasiveness in in vitro and in vivo studies 
(Azimi, Roberts-Thomson, & Monteith, 2014). Recently the Ca2+ permeable ion channel 
TRPC1 was identified as a positive modulator of pAKT levels in PTEN-deficient breast 
cancer cell lines, whereby TRPC1 silencing decreases basal pAKT levels (Azimi, et al., 
2017). The potential role of other calcium channels or even specific calcium pumps to 
regulate pAKT in PTEN-deficient breast cancer cells has not been fully explored. The 
pharmacological modulation of such calcium channels and pumps may provide an 
opportunity to reduce AKT activation in breast cancer cells without the possible systemic 
side effects of global AKT inhibition. Such agents could be used in combination with or 
instead of direct AKT inhibitors, e.g. MK-2206, used in a clinical trial for advanced breast 
cancers to improve treatment outcome (ClinicalTrials.gov). This paper is specifically for 
academic laboratories who are considering or planning to use an automated epi-
fluorescence microscopy approach for targeted smaller scale screens for pAKT effects, the 
methodological considerations and validation approaches are described and discussed 
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Material and methods 
Cell culture 
HCC-1569 cells were maintained in RPMI-1640 media (Sigma Aldrich, R8757) 
supplemented with 10 % fetal bovine serum (FBS) (complete growth media), at 37 °C with 5 
% CO2. Cells were routinely tested for mycoplasma contamination (MycoAlert, Lonza, Basel, 
Switzerland) and authenticated by STR profiling (GenePrint 10 system; Promega, Madison, 
WA, USA) at QIMR Berghofer, Brisbane, Australia.  
 
siRNA transfection 
Cells were seeded into 96-well black-walled clear bottom imaging plates (353219, BD 
Biosciences) at a density of 5000 cells/well and transfected with siRNA 24 h after seeding. 
For siRNA experiments cells were treated with Dharmacon ON-TARGETplus SMARTpool 
siRNA (GE Dharmacon, Lafayette, CO, USA) at a final concentration of 100 nM/well and 
DharmaFECT4 transfection reagent (0.1 µL/well, Dharmacon, T-2004-01) in media 
containing 8 % FBS, according to the company’s recommended protocol. The following 
Dharmacon ON-TARGETplus SMARTpool siRNAs were used in this study: Non-targeting 
(D-001810-10-05), TRPC1 (L-004191-00-0005), TRPV6 (L-003607-00-0005), STIM1 (L-
011785-00-0005), ORAI1 (L-014998-00-0005), PMCA1 (L-006115-00-0005), PMCA2 (L-
006116-00-0005), PMCA4 (L-006118-00-0005), SPCA1 (L-006119-00-0005) and SPCA2 (L-
006280-00-0005). These targets were assessed due to their potential contribution to basal 
and/or trans-golgi network Ca2+ levels.  
 
Induction and inhibition of AKT phosphorylation using EGF and MK-2206  
Forty-eight hours post siRNA transfection cell culture medium was serum reduced (0.5 % 
FBS) for 24 h before cells were treated with 1 µM of AKT Inhibitor MK-2206 2HCl 
(Selleckchem, 1032350) or 0.1 % DMSO (vehicle control) in serum reduced media. AKT 
phosphorylation was induced 24 h after inhibitor treatement with EGF (60 ng/mL; Sigma-
Aldrich, E9644) or vehicle control (0.5 µM acetic acid) in serum reduced media for 20-25 
min. Cells were then fixed and stained as described below. 
 
Immunofluorescence 
Plates were chilled on ice and cells were washed twice with Phosphate Buffered Saline 
(PBS) containing 0.1 mM CaCl2, 1 mM MgCl2 (PBSCM). Cells were fixed with 4 % PFA 
(Pierce, Thermo Fischer Scientific, 28906) in PBSCM for 20 min, washed once in 
PBSCM/0.1 M Glycine, twice in PBS/CM and then permeabilized with 0.2 % (v/v) Triton-X-
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100/PBSCM for 10 min before washed 3 times in PBSCM. Cells were then incubated in 
blocking buffer (PBSCM and 1 % BSA) for 1 h at room temperature before incubation with 
primary antibody (pAKT (Ser473), 4060 Cell Signaling) at a 1:100 dilution in blocking buffer 
(PBSCM and 1 % BSA) overnight at 4 °C. Cells were washed 3 times in PBSCM before 
incubation with secondary antibody in blocking buffer (anti-Rabbit IgG, Alexa Fluor
®
 488 
Conjugate, 4412 Cell Signaling) at a 1:1000 dilution for 1 h at room temperature. Cells were 
washed twice before nuclei were stained using 2 µg/mL DAPI in PBSCM for 10 min and 
washed twice in PBSCM before cells were imaged in PBS. All steps were performed using 
an electronic multichannel pipette at low speed to minimize cell loss during this staining 
protocol. 
 
Image acquisition and analysis 
Cells were imaged using an ImageXpress Micro automated epifluorescence microscope 
(Molecular Devices, Sunnyvale CA, USA) with a 10x objective and the following 
excitation/emission filters: wavelength 377–450 nm/447-60 nm for DAPI (W1: DAPI filter) 
and 472-530 nm/520-630 nm for Alexa488 (W2: GFP filter). Images of duplicate wells in 
each plate were acquired with 100 ms (DAPI filter, nuclei) and 4357 ms (GFP filter, pAKT) 
exposure times. Seven sites per well were imaged (sites were separate from each other to 
avoid photo bleaching). Laser based autofocusing was used for each site. For single cell 
analysis images were acquired and analyzed using the MetaXpress software. Cells were 
identified for nuclear count using the following parameters, nuclei staining with a minimum of 
10 and maximum of 40 µm widths (16-62 pixels) and an intensity of 1000 graylevels above 
local background. For pAKT staining, cells were identified with a cytoplasm staining with a 
minimum of 15 µm and a maximum of 80 µm widths (23-124 pixels) and an intensity of 80 
graylevels above local background. 
 
Immunoblotting 
Protein was isolated from eight pooled wells of a 96-well plate using protein lysis buffer 
supplemented with protease and phosphatase inhibitors (Roche Applied Science, Penzberg, 
Germany). Gel electrophoresis was performed using mini protean TGX stain free precast 
gels (Bio-Rad, Gladesville, New South Wales) with 1x TGX running buffer (Bio-Rad) and 
transferred to a PVDF membrane (Bio-Rad) using the Trans Blot Turbo Transfer system 
(Bio-Rad). Membranes were blocked in 0.1 % PBST + 5 % skim milk for 1 h. Primary pAKT 
antibody (Phospho-Akt (Ser473), 4051, Cell Signaling) and AKT antibody (Akt Antibody, 
9272, Cell Signaling) were diluted 1:1000 in blocking buffer and incubated at 4 °C overnight. 
The following secondary antibodies were used; anti-mouse HRP-conjugated secondary 
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(170–6516, Bio-Rad) and anti-rabbit HRP-conjugated secondary (170–6515 BioRad) at 1:10 
000 dilution. Images were acquired using the Chemidoc Touch Imaging System (Bio-Rad), 
analyzed using the ImageLab software version 5.2.1 (Bio-Rad) and local background 
subtraction. Protein density was normalized to beta actin loading controls and pAKT protein 
expression was normalized to total AKT protein expression as previously described (Azimi, 
et al., 2017).  
 
Data analysis and statistics 
Single cell data from seven fields/well were analyzed using MetaXpress and exported to 
Excel, zero values were not further analyzed. All data was log transformed and statistical 
analysis was performed using GraphPad Prism. Tests used for statistical significance are 
found in each figure legend.  
 
Formulas 
 
Standard score  
𝑆𝑆 =
𝑋𝑐𝑒𝑙𝑙−𝜇𝑝𝑙𝑎𝑡𝑒
𝜎𝑝𝑙𝑎𝑡𝑒
  
X = log cytoplasmic intensity of pAKT staining of a single identified cell 
µplate = mean of log cytoplasmic intensity of pAKT staining of all identified cells per plate, for 
all treatments (control, EGF and MK-2206 treated cells in duplicate wells per plate) 
σplate = standard deviation of log cytoplasmic intensity of pAKT staining of all identified cells 
per plate (control, EGF and MK-2206 treated cells in duplicate wells per plate) 
 
z’ factor 
𝑧′ = 1 −
3(𝜎𝑝𝑜𝑠+𝜎𝑛𝑒𝑔 )
|𝜇𝑝𝑜𝑠−𝜇𝑛𝑒𝑔 |
   
σpos = standard deviation of log cytoplasmic intensity of pAKT staining of all identified cells in 
positive control wells (EGF treated cells) of all 3 experiments 
σpos = standard deviation of log cytoplasmic intensity of pAKT staining of all identified cells in 
negative control wells (MK-2206 treated cells) of all 3 experiments 
µpos = mean of log cytoplasmic intensity of pAKT staining of all identified cells in positive 
control wells (EGF treated cells) of all 3 experiments 
µneg = mean of log cytoplasmic intensity of pAKT staining of all identified cells in negative 
control wells (MK-2206 treated cells) of all 3 experiments  
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Results  
In this study, we present an assay with increased throughput suitable to identify potential 
modulators of AKT phosphorylation using immunofluorescence imaging with an automated 
epifluorescence microscope and high content analysis. This assay was optimized using the 
PTEN deficient breast cancer cell line (HCC-1569), which exhibits high basal levels of pAKT, 
and positive and negative controls, EGF (induces AKT phosphorylation, positive control)  
(Henson & Gibson, 2006) and the pharmacological AKT inhibitor MK-2206 (reduces AKT 
phosphorylation negative control) (Hirai, et al., 2010).  
 
The first step to establish our assay protocol was to assess pAKT levels in HCC-1569 cells 
after treatment with a known negative and a known positive pAKT modulator using 
immunofluorescence imaging. We then compared the log integrated cytoplasmic staining 
intensity for pAKT. HCC-1569 cells were treated with vehicle control (Fig. 1Ai), a 
pharmacological AKT Inhibitor (MK-2206) (Fig. 1Aii) or stimulated with EGF (Fig 1Aii i) and 
imaged using an automated epifluorescence microscope. As expected, basal AKT 
phosphorylation levels appeared to increase with EGF and decrease with MK-2206 
treatment. This data was then analyzed using high content imaging analysis, with an inbuilt 
algorithm for nuclear cell count (MetaXpress) to identify cells and to assess their log 
integrated cytoplasmic intensity for pAKT staining (Fig. 1B). Treatment with MK-2206 
resulted in a significant reduction of the integrated log cytoplasmic intensity compared to 
vehicle controls, whereas EGF treatment significantly increased the pAKT level (Fig. 1B). 
 
Although significant, the mean of the raw data values of the integrated log cytoplasmic 
intensity between treatments was very similar and thus the assay window very small. To be 
able to compare raw data sets of log cytoplasmic intensity values and to improve the assay 
window, different normalization methods were applied (Fig 2).  To identify the most robust 
normalization approach and optimal analysis method for this assay, the z’ factor was 
calculated for each method. The z’ factor is a statistically measurement widely used in high 
throughput screening to determine the robustness of an assay and to determine intra-plate 
variability (Zhang, Chung, & Oldenburg, 1999), a z’ factor < 0 indicating a poor assay quality, 
a z’ factor between 0 to 0.5 is considered suitable for medium throughput screening, while a 
score between 0.5 to 1 is indicative of an assay suitable for high throughput screening. We 
sought to use the z’ factor to assess the effect of different normalization methods on the 
quality of this assay, by comparing normalized data sets from 3 different experiments. The 
log integrated cytoplasmic intensity was analyzed in duplicate wells per treatment (Fig 2A). A 
high inter-plate variability was observed, whereas technical replicates on each plate showed 
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high reproducibility (Fig. 2A), resulting in a poor z’ factor for a biomolecular screen (z' = -
2.64). The mean of each replicate was normalized to the mean of the two control wells of the 
same plate to calculate the fold change (Fig. 2B), and this improved assay robustness (z' = 
0). The standard score of the mean represents a potentially more robust way to normalize 
data, and this resulted in a z’ factor of 0.37 (Fig. 2C). In addition to the mean, we compared 
different percentiles of the cytoplasmic intensity between the treatments. Leading us to adopt 
the standard score of the median, which had the highest z’ factor and provided the largest 
assay window (z' = 0.45) (Fig. 2D).  
 
Some calcium transporting proteins are involved in mediating drug resistance and are 
involved in pAKT regulation. Thus, we sought to examine the effect of gene silencing of nine 
different calcium homeostasis regulating proteins on pAKT levels in HCC-1569 breast 
cancer cells using our image based assay and optimized data normalization method (Fig 3). 
Gene silencing experiments were performed over 7 days (Fig 3A) and images were 
processed using high content imaging analysis (Fig 3B). As expected the positive control, 
EGF treatment, increased the median standard score and the negative control, MK-2206 
treatment, reduced the standard score compared to siNT controls. Values higher than the 
mean of the median standard score for siNT controls were categorized as positive pAKT 
potential modulators (Fig 3C, above dotted line) and values lower as negative pAKT 
potential modulators (Fig 3C, below dotted line). Silencing of PMCA1, PMCA2 and PMCA4 
did not affect the pAKT level, as values were similar to the control (siNT). In contrast, the 
silencing of SPCA1 and SPCA2 resulted in an increase of the median standard score, 
similar to EGF treated samples (Fig 3C). As we aimed to identify targets that when silenced 
reduced basal pAKT levels in HCC-1569 breast cancer cells, these targets were not further 
investigated.  
 
Silencing of TRPV6, ORAI1, STIM1 and TRPC1 reduced pAKT level. The greatest reduction 
in pAKT levels was observed when TRPC1 was silenced, with a median standard score for 
the integrated log cytoplasmic intensity, similar to cells treated with MK-2206 (Fig 3C). 
TRPV6 silencing showed the second lowest standard score in this assay. Silencing of STIM1 
reduced the median standard score only slightly and values were just lower than the lowest 
value of the control. Although ORAI1 silencing resulted in a reduction of the median standard 
score compared to the siNT control, these values were within the standard deviation of the 
controls. Thus, ORAI1 was not further investigated. 
 
To confirm hits identified with our imaging based assay, an alternative low throughput 
method (immunoblotting) was used. Three targets, TRPC1, TRPV6 and STIM1, identified in 
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this screen as showing high, moderate and weak reduction of log cytoplasmic intensity 
compared to controls respectively, were validated using immunoblotting and a different 
primary antibody (optimized for immunoblotting) (Fig. 4A).  
 
These three targets were silenced and experiments were performed following the described 
timeline with protein isolation for immunoblotting on day 6 instead of sample processing for 
immunofluorescence (Fig 3A). Immunoblotting results confirmed that silencing of all three 
targets reduced pAKT levels. Silencing of TRPV6 showed a 34 % reduction of pAKT levels 
compared to controls while silencing of STIM1 reduced pAKT levels by 56 %. Consistent 
with the automated immunofluorescence assay TRPC1 had the most pronounced effect on 
pAKT levels with a reduction of 71 % (Fig 4B). This immunoblotting assay confirmed the 
results of the high content imaging approach, suggesting the suitability of this image-based 
assay to identify new modulators of pAKT in PTEN deficient breast cancer cells. 
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Discussion 
 
AKT phosphorylation is an important cellular regulatory switch of various downstream 
signaling pathways, many of which are relevant to cancer progression (Luo, et al., 2003; 
Yang, et al., 2015). Elevated levels of pAKT are found in breast cancers with loss of PTEN, 
as well as breast cancers with BRCA1 mutations or HER2 overexpression (Clark, et al., 
2002; Vara, et al., 2004; Yi, et al., 2013). The PIP3/AKT pathway is involved in suppressing 
apoptosis, stimulating cell cycle progression and contributes to resistance to radiation and 
targeted therapy (Albert, Kim, Cao, & Lu, 2006; O'Brien, et al., 2010). Targeting AKT 
phosphorylation might present a new therapeutic approach to improve current management 
of advanced breast cancers (Hirai, et al., 2010; Luo, et al., 2003). This study presents a 
simple protocol to identify pAKT modulators using an automated epifluorescence imaging 
system and high content imaging analysis, rather than immunoblotting to quantify and 
compare AKT phosphorylation (Lin, Hsieh, Song, & Lin, 2005). Our assay protocol increases 
throughput and has been proven to be suitable to detect pAKT modulators. We showed that 
our automated epifluorescence microscopy based assay can identify modulators of AKT 
phosphorylation with medium throughput. During development of this assay, we consistently 
showed a signal increase in log cytoplasmic intensity for pAKT staining in HCC-1569 cells 
treated with the positive modulator (EGF) and a decrease for cells treated with the negative 
modulator (MK-2206) compared to pAKT levels in controls. However, we observed a high 
inter-plate variability, thus we sought to explore different normalization methods. A widely 
used method to normalize treated samples to controls is the fold change or ‘fraction of 
control’. Our data set was analyzed using this method normalizing the mean of each 
treatment (siNT + EGF, siNT + MK-2206) to the siNT control. However, this normalization 
method does not account for inter-plate variation of the log integrated cytoplasmic intensity. 
Thus, we used the standard score to normalize the data sets. The standard score converts 
the log integrated cytoplasmic intensity for pAKT staining for each individual cell into the 
number of standard deviations it differs from the plate mean, which resulted in a higher z’ 
factor (Malo, Hanley, Cerquozzi, Pelletier, & Nadon, 2006). Once the standard score was 
determined to be a suitable method for data normalization, the assay was further optimized 
by comparing different statistical measurements. The median standard score value resulted 
in the highest z’ factor. 
 
As part of validating the new assay, we also assessed the effect of various calcium 
homeostasis regulating proteins on AKT phosphorylation in HCC-1569 breast cancer cells. 
Altered expression of calcium homeostasis regulating proteins has been associated with 
drug resistance in some breast cancer cells. For example, the transient receptor potential 
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channel TRPC5 promotes adriamycin resistance in MCF-7/ADM breast cancer cells (Ma, et 
al., 2012). Another study showed that silencing the calcium pump plasma membrane Ca2+-
ATPase 2 (PMCA2) in MDA-MB-231 basal breast cancer cells increased the efficacy of the 
chemotherapeutic doxorubicin (Peters, et al., 2016). TRPC1 and STIM1 have been linked to 
transforming growth factor β (TGFβ)-induced epithelial-to-mesenchymal transition (EMT) 
and to cancer metastasis in breast cancer (Schaar, Sukumaran, Sun, Dhasarathy, & Singh, 
2016). A recent study showed that TRPC1 is a key regulator of a variety of hypoxia mediated 
changes and AKT signaling in PTEN deficient MDA-MB-468, TRPC1 was also shown to 
regulate AKT phosphorylation in HCC-1569 breast cancer cells (Azimi, et al., 2017). The 
mechanism by which TRPC1 contributes to pAKT and proliferation in breast cancer is likely 
multifactorial, but there is strong evidence for the involvement of TRPC1 in the regulation of 
basal Ca2+ influx in another PTEN deficient breast cancer cell line, MDA-MB-468 (Davis, et 
al., 2012). The finding that STIM1 reduced pAKT levels is of interest given the reports of 
STIM1 regulation of TRPC1-mediated effects in some cells (Huang, et al., 2006; Ng, et al., 
2009; Schaar, et al., 2016). AKT phosphorylation may be dependent on basal calcim influx  
since TRPV6 silencing significantly reduced pAKT levels in HCC-1569 cells and TRPV6 is a 
constitutively active Ca2+ channel and a key regulator of basal Ca2+ influx (Peters, et al., 
2012; Raphaël & Prevarskaya, 2012). 
 
High content analysis allows the simultaneous assessment of a variety of phenotypic 
characteristics using a high throughput approach (Buchser, et al., 2004). Our assay was 
optimized for increased throughput to assess potential pAKT modulators, using a simple 
protocol, with inbuilt algorithms for assessment of cytosolic pAKT and the standard score 
normalization method. This assay facilitated the assessment of the effect of silencing 
proteins involved in calcium signaling on AKT phosphorylation and has the potential to 
identify other modulators of AKT phosphorylation. The molecular AKT modulators identified 
here (TRPC1, STIM1 and TRPV6) should now be further assessed using downstream 
assays to further define their roles in the pAKT/PIP3 pathway. 
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Fig 1: Induction and inhibition of AKT phosphorylation in HCC-1569 cells. pAKT levels 
in HCC-1569 cells transfected with siNT (vehicle control, Ai), treated with the AKT inhibitor 
MK-2206 for 24 h (Aii), or 60 ng/mL EGF for 20-25 min (Aiii). Images were acquired using an 
automated epifluorescence microscope (ImageXpress, Molecular Devices) a DAPI filter set 
(Ex 377-450 nm/Em 447-560 nm) and a GFP filter set (Ex 472-530 nm/Em 520-535 nm). 
Images show nuclei in blue (DAPI staining, left panel), pAKT staining in green (Alexa Fluor® 
488 Conjugate, mid panel) and the composite image of both images (right panel) (A). pAKT 
levels were analyzed in cells meeting criteria for signal intensity and stained area for both 
channels described in material and methods. Cytoplasmic intensity of the green channel 
(pAKT) was determined for controls, cells treated with the AKT inhibitor MK-2206 or EGF (n 
= 3 independent biological repeats, with 2 technical replicates ± SD, shown are 3000 
randomized data points per treatment) (B). Statistical analysis was performed after log 
transformation compared to siNT using a one-way ANOVA with Dunnett’s multiple 
comparison post-hoc analysis (p ****< 0.0001 ).  
 
Fig 2: Assessment of log integrated cytoplasmic intensity of pAKT levels in HCC-1569 
cells using different normalization methods. Values for log integrated cytoplasmic 
intensity, and z’ factors are shown for mean (A), fold change (B), standard score of mean log 
integrated cytoplasmic intensity (C) and standard score of median log integrated cytoplasmic 
intensity (D) for HCC-1569 cells treated with siNT, siNT +EGF and siNT+ MK-2206 (n = 3 
independent biological repeats, with 2 technical replicates ± SD).  
 
Fig 3: Effect of silencing calcium homeostasis regulating proteins on pAKT levels in 
HCC-1569 breast cancer cells. Timeline for cell treatment (A). For image analysis, the multi 
wavelength scoring tool with a standard algorithm based on scoring for nuclei using 
wavelength 1, (W1: DAPI filter, B top panel) and cytoplasmic staining for pAKT using 
wavelength 2 (W2: GFP filter, B bottom panel) were applied. Identified objects for W1 are 
shown in white and for W2 in red (B). Calcium homeostasis regulating proteins were 
silenced and the standard score for median log cytoplasmic integrated intensity was 
compared to the mean of median standard score for the siNT controls (C). Values for the 
negative control (MK-2206) and the positive control (EGF) are also shown. Positive pAKT 
modulators were identified with values higher than the median standard score for siNT 
(above the dotted line) and negative pAKT modulators with lower values, non-targeting 
siRNA (siNT), TRPC1 siRNA (siTRPC1), TRPV6 siRNA (siTRPV6), ORAI1 siRNA 
(siORAI1), STIM1 siRNA (siSTIM1), SPCA1 siRNA (siSPCA1), SPCA2 siRNA (siSPCA2), 
PMCA1 siRNA (siPMCA1), PMCA2 siRNA (siPMCA2) or PMCA4 siRNA (siPMCA4) (siNT, 
siNT + EGF, siNT + MK-2206, n = 3 biological replicates, with 2 technical replicates; 
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silencing calcium homeostasis regulating proteins n = 1 biological replicate, 2 technical 
replicates). 
 
Fig 4: Confirmation of identified negative pAKT modulators, TRPC1, STIM1 and TRPV6 
using immunoblotting. Cells were treated with non-targeting siRNA (siNT), TRPV6 siRNA 
(siTRPV6), STIM1 siRNA (siSTIM1) or TRPC1 siRNA (siTRPC1). Representative 
immunoblots for pAKT, total AKT and their corresponding loading controls are shown in (A). 
pAKT and total AKT protein expression were normalized to the beta actin loading control and 
pAKT levels were expressed as relative to total AKT level (B). All bar graphs are mean ± SD 
(n = 3 biological replicates). Statistical analysis was performed using one-way ANOVA with 
Dunnett’s multiple comparison post-hoc analysis comparing all treatments to siNT control (*p 
≤ 0.05, p** ≤ 0.01, p*** ≤ 0.001).  
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